60 Degrees Pharmaceuticals (SXTP) Change in Accured Expenses (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Change in Accured Expenses of $11735.0 for Q1 2026, down 95.52% year-over-year from $261905.0 in Q1 2025, and down 67.13% quarter-over-quarter from $35705.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Change in Accured Expenses (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Change in Accured Expenses for 5 consecutive years, with $11735.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 95.52% year-over-year to $11735.0; the TTM figure through Mar 2026 stood at $240913.0 (down 67.45% YoY), while the FY2025 annual figure was $491083.0, down 2.06% from the prior year.
- Change in Accured Expenses slipped to $11735.0 in Q1 2026 per SXTP's latest filing, from $35705.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $445639.0 in Q3 2025 and bottomed at -$399653.0 in Q3 2023.
- Historically, Change in Accured Expenses has averaged $78575.7 across 5 years, with a median of $62526.5 in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 1026.81% in 2025 and fell as far as 351.78% in 2025.
- 60 Degrees Pharmaceuticals' Change in Accured Expenses stood at -$29167.0 in 2022, then tumbled by 1270.22% to -$399653.0 in 2023, then soared by 182.57% to $330001.0 in 2024, then tumbled by 89.18% to $35705.0 in 2025, then plunged by 67.13% to $11735.0 in 2026.
- Business Quant data shows SXTP's Change in Accured Expenses at $11735.0 in Q1 2026, $35705.0 in Q4 2025, and $445639.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -262,817.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,735.00 |
| Mar 31, 2026 | 11,735.00 |
| Dec 31, 2025 | 35,705.00 |
| Dec 31, 2025 | 35,705.00 |
| Sep 30, 2025 | 445,639.00 |
| Sep 30, 2025 | 445,639.00 |
| Jun 30, 2025 | -252,166.00 |
| Jun 30, 2025 | -252,166.00 |
| Mar 31, 2025 | 261,905.00 |
| Mar 31, 2025 | 261,905.00 |
| Dec 31, 2024 | 330,001.00 |
| Dec 31, 2024 | 330,001.00 |
| Sep 30, 2024 | 48,015.00 |
| Sep 30, 2024 | 48,015.00 |
| Jun 30, 2024 | 100,153.00 |
| Jun 30, 2024 | 100,153.00 |
| Mar 31, 2024 | 23,243.00 |
| Mar 31, 2024 | 23,243.00 |
| Sep 30, 2023 | -399,653.00 |
| Sep 30, 2023 | -399,653.00 |